https://scholars.lib.ntu.edu.tw/handle/123456789/495145
標題: | Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials | 作者: | SUNG-HSIN KUO CHIH-HSIN YANG CHONG-JEN YU CHIUN HSU ANN-LII CHENG PAN-CHYR YANG |
公開日期: | 2005 | 出版社: | Elsevier Ireland Ltd | 卷: | 48 | 期: | 2 | 起(迄)頁: | 275-280 | 來源出版物: | Lung Cancer | 摘要: | This study was designed to compare the outcome of stage IIIB/IV non-small cell lung cancer patients who were treated with chemotherapy but did not participate in clinical trials of first-line chemotherapy with patients that had been treated with three clinical trials during this period. From October 1997 through October 1999, 132 patients (stage IIIB, 31 patients; stage IV, 101 patients) who received at least one dose of chemotherapy but did not participate in first-line chemotherapy trials were included. Response was evaluated in 132 patients. Six (4.5%) achieved a complete response and 32 (24.3%) achieved a partial response, resulting in an overall response rate of 28.8% (95% CI, 21.0-36.6). The median overall survival for all 132 patients was 11 months (95% CI, 9.5-12.5), and the median progression-free survival was 4.2 months (95% CI, 3.4-5.0). The median overall and progression-free survival for patients (N = 129) who participated in one of three clinical trials during the study period was 13.5 months (95% CI, 11.2-15.8) and 5.6 months (95% CI, 4.9-6.0), respectively. There was no significant difference in overall and progression-free survival between patients who did or did not participate in clinical trials (overall survival: P = 0.36; progression-free survival: P = 0.57). Our data suggest that the survival of patients who received chemotherapy but did not participate in clinical trials was similar to patients participated in clinical trials. ? 2004 Elsevier Ireland Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-17044369997&doi=10.1016%2fj.lungcan.2004.10.004&partnerID=40&md5=e55ac69a233c57add3fca6566656c426 https://scholars.lib.ntu.edu.tw/handle/123456789/495145 |
ISSN: | 0169-5002 | DOI: | 10.1016/j.lungcan.2004.10.004 | SDG/關鍵字: | cisplatin; epirubicin; gemcitabine; adult; aged; article; cancer combination chemotherapy; cancer growth; cancer patient; cancer staging; cancer survival; comparative study; controlled study; drug response; female; human; lung non small cell cancer; major clinical study; male; patient selection; priority journal; survival rate; survival time |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。